A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism

A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Un...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anesthesiology (Philadelphia) 2003-04, Vol.98 (4), p.906-911
Hauptverfasser: JOOSTE, Edmund, KLAFTER, Farrah, HIRSHMAN, Carol A, EMALA, Charles W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 911
container_issue 4
container_start_page 906
container_title Anesthesiology (Philadelphia)
container_volume 98
creator JOOSTE, Edmund
KLAFTER, Farrah
HIRSHMAN, Carol A
EMALA, Charles W
description A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction. Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors. Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants. Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.
doi_str_mv 10.1097/00000542-200304000-00017
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmed_primary_12657852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12657852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-646796e10eb001c0703f7703a08a11cdd1ae3aff270a9e7e5557c378226abc163</originalsourceid><addsrcrecordid>eNpFkEtLAzEUhYMotlb_gmTjMprH5FF3pfiCipu6Hu5kEhtpZoaks_Dfm9qqgeRywjmXez-EMKO3jM71Hd0fWXHCKRW0KoKUy_QJmjLJDWFMy1M0LX-CCMr5BF3k_FmklsKcownjSmoj-RStFzg6u4Eu5Ih9n3CCAeyY-i6MkYSuHa1rcVO03fR5gBzv8SvHccwWUuiCxclZN-xKErodfPT7RpfozMM2u6tjnaH3x4f18pms3p5elosVsdyoHVGV0nPlGHVNGd5STYXX5QFqgDHbtgycAO-5pjB32kkptRXacK6gsUyJGTKHvjb1OSfn6yGFCOmrZrTeg6p_QdV_oOofUCV6fYgOYxNd-x88kimGm6MByqpbn6CzIf_7Kl0gV0Z8A-K1cIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>JOOSTE, Edmund ; KLAFTER, Farrah ; HIRSHMAN, Carol A ; EMALA, Charles W</creator><creatorcontrib>JOOSTE, Edmund ; KLAFTER, Farrah ; HIRSHMAN, Carol A ; EMALA, Charles W</creatorcontrib><description>A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction. Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors. Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants. Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</description><identifier>ISSN: 0003-3022</identifier><identifier>EISSN: 1528-1175</identifier><identifier>DOI: 10.1097/00000542-200304000-00017</identifier><identifier>PMID: 12657852</identifier><identifier>CODEN: ANESAV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Animals ; Atracurium - pharmacology ; Binding, Competitive - drug effects ; Biological and medical sciences ; Bronchial Spasm - chemically induced ; Bronchial Spasm - physiopathology ; Cell Membrane - drug effects ; CHO Cells ; Cricetinae ; Diamines - pharmacology ; Drug toxicity and drugs side effects treatment ; Indicators and Reagents ; Medical sciences ; Muscarinic Antagonists ; Neuromuscular Nondepolarizing Agents - toxicity ; Pharmacology. Drug treatments ; Piperidines - pharmacology ; Quinuclidinyl Benzilate - pharmacology ; Radioligand Assay ; Receptor, Muscarinic M2 ; Receptor, Muscarinic M3 ; Receptors, Muscarinic - drug effects ; Toxicity: respiratory system, ent, stomatology ; Vecuronium Bromide - analogs &amp; derivatives ; Vecuronium Bromide - pharmacology ; Vecuronium Bromide - toxicity</subject><ispartof>Anesthesiology (Philadelphia), 2003-04, Vol.98 (4), p.906-911</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14711748$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12657852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JOOSTE, Edmund</creatorcontrib><creatorcontrib>KLAFTER, Farrah</creatorcontrib><creatorcontrib>HIRSHMAN, Carol A</creatorcontrib><creatorcontrib>EMALA, Charles W</creatorcontrib><title>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</title><title>Anesthesiology (Philadelphia)</title><addtitle>Anesthesiology</addtitle><description>A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction. Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors. Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants. Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</description><subject>Animals</subject><subject>Atracurium - pharmacology</subject><subject>Binding, Competitive - drug effects</subject><subject>Biological and medical sciences</subject><subject>Bronchial Spasm - chemically induced</subject><subject>Bronchial Spasm - physiopathology</subject><subject>Cell Membrane - drug effects</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Diamines - pharmacology</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Indicators and Reagents</subject><subject>Medical sciences</subject><subject>Muscarinic Antagonists</subject><subject>Neuromuscular Nondepolarizing Agents - toxicity</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - pharmacology</subject><subject>Quinuclidinyl Benzilate - pharmacology</subject><subject>Radioligand Assay</subject><subject>Receptor, Muscarinic M2</subject><subject>Receptor, Muscarinic M3</subject><subject>Receptors, Muscarinic - drug effects</subject><subject>Toxicity: respiratory system, ent, stomatology</subject><subject>Vecuronium Bromide - analogs &amp; derivatives</subject><subject>Vecuronium Bromide - pharmacology</subject><subject>Vecuronium Bromide - toxicity</subject><issn>0003-3022</issn><issn>1528-1175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtLAzEUhYMotlb_gmTjMprH5FF3pfiCipu6Hu5kEhtpZoaks_Dfm9qqgeRywjmXez-EMKO3jM71Hd0fWXHCKRW0KoKUy_QJmjLJDWFMy1M0LX-CCMr5BF3k_FmklsKcownjSmoj-RStFzg6u4Eu5Ih9n3CCAeyY-i6MkYSuHa1rcVO03fR5gBzv8SvHccwWUuiCxclZN-xKErodfPT7RpfozMM2u6tjnaH3x4f18pms3p5elosVsdyoHVGV0nPlGHVNGd5STYXX5QFqgDHbtgycAO-5pjB32kkptRXacK6gsUyJGTKHvjb1OSfn6yGFCOmrZrTeg6p_QdV_oOofUCV6fYgOYxNd-x88kimGm6MByqpbn6CzIf_7Kl0gV0Z8A-K1cIg</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>JOOSTE, Edmund</creator><creator>KLAFTER, Farrah</creator><creator>HIRSHMAN, Carol A</creator><creator>EMALA, Charles W</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030401</creationdate><title>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</title><author>JOOSTE, Edmund ; KLAFTER, Farrah ; HIRSHMAN, Carol A ; EMALA, Charles W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-646796e10eb001c0703f7703a08a11cdd1ae3aff270a9e7e5557c378226abc163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Atracurium - pharmacology</topic><topic>Binding, Competitive - drug effects</topic><topic>Biological and medical sciences</topic><topic>Bronchial Spasm - chemically induced</topic><topic>Bronchial Spasm - physiopathology</topic><topic>Cell Membrane - drug effects</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Diamines - pharmacology</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Indicators and Reagents</topic><topic>Medical sciences</topic><topic>Muscarinic Antagonists</topic><topic>Neuromuscular Nondepolarizing Agents - toxicity</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - pharmacology</topic><topic>Quinuclidinyl Benzilate - pharmacology</topic><topic>Radioligand Assay</topic><topic>Receptor, Muscarinic M2</topic><topic>Receptor, Muscarinic M3</topic><topic>Receptors, Muscarinic - drug effects</topic><topic>Toxicity: respiratory system, ent, stomatology</topic><topic>Vecuronium Bromide - analogs &amp; derivatives</topic><topic>Vecuronium Bromide - pharmacology</topic><topic>Vecuronium Bromide - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JOOSTE, Edmund</creatorcontrib><creatorcontrib>KLAFTER, Farrah</creatorcontrib><creatorcontrib>HIRSHMAN, Carol A</creatorcontrib><creatorcontrib>EMALA, Charles W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Anesthesiology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JOOSTE, Edmund</au><au>KLAFTER, Farrah</au><au>HIRSHMAN, Carol A</au><au>EMALA, Charles W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism</atitle><jtitle>Anesthesiology (Philadelphia)</jtitle><addtitle>Anesthesiology</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>98</volume><issue>4</issue><spage>906</spage><epage>911</epage><pages>906-911</pages><issn>0003-3022</issn><eissn>1528-1175</eissn><coden>ANESAV</coden><abstract>A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation. Rapacuronium, which sought to fulfill these criteria, was withdrawn from clinical use due to a high incidence of bronchospasm resulting in death. Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clinically. Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction. Competitive radioligand binding determined the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors. Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clinically relevant concentrations. Fifty percent inhibitory concentrations (mean +/- SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10 +/- 1.5 microm (n = 6); M3 muscarinic receptor, 77.9 +/- 11 microm (n = 8). Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clinically achieved concentrations for these relaxants. Rapacuronium in clinically significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors. A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>12657852</pmid><doi>10.1097/00000542-200304000-00017</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-3022
ispartof Anesthesiology (Philadelphia), 2003-04, Vol.98 (4), p.906-911
issn 0003-3022
1528-1175
language eng
recordid cdi_pubmed_primary_12657852
source MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals
subjects Animals
Atracurium - pharmacology
Binding, Competitive - drug effects
Biological and medical sciences
Bronchial Spasm - chemically induced
Bronchial Spasm - physiopathology
Cell Membrane - drug effects
CHO Cells
Cricetinae
Diamines - pharmacology
Drug toxicity and drugs side effects treatment
Indicators and Reagents
Medical sciences
Muscarinic Antagonists
Neuromuscular Nondepolarizing Agents - toxicity
Pharmacology. Drug treatments
Piperidines - pharmacology
Quinuclidinyl Benzilate - pharmacology
Radioligand Assay
Receptor, Muscarinic M2
Receptor, Muscarinic M3
Receptors, Muscarinic - drug effects
Toxicity: respiratory system, ent, stomatology
Vecuronium Bromide - analogs & derivatives
Vecuronium Bromide - pharmacology
Vecuronium Bromide - toxicity
title A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20mechanism%20for%20rapacuronium-induced%20bronchospasm:%20M2%20muscarinic%20receptor%20antagonism&rft.jtitle=Anesthesiology%20(Philadelphia)&rft.au=JOOSTE,%20Edmund&rft.date=2003-04-01&rft.volume=98&rft.issue=4&rft.spage=906&rft.epage=911&rft.pages=906-911&rft.issn=0003-3022&rft.eissn=1528-1175&rft.coden=ANESAV&rft_id=info:doi/10.1097/00000542-200304000-00017&rft_dat=%3Cpubmed_cross%3E12657852%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12657852&rfr_iscdi=true